Logo

MIRA

MIRA Pharmaceuticals, Inc.

MIRA

MIRA Pharmaceuticals, Inc. • NASDAQ
$1.48 ▲ 0.68% (+0.01)
Market Cap $61.96 M
52w High $2.45
52w Low $0.73
Dividend Yield 0%
P/E -0.92
Volume 93.45K
Outstanding Shares 41.87M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.317M ▼ $-22.694M ▼ 0% $-1.18 ▼ $-1.138M ▲
Q2-2025 $0 $1.546M ▼ $-1.538M ▲ 0% $-0.09 ▲ $-1.546M ▲
Q1-2025 $0 $1.805M ▼ $-1.784M ▲ 0% $-0.11 ▲ $-1.805M ▲
Q4-2024 $0 $2.438M ▲ $-2.4M ▼ 0% $-0.16 ▼ $-2.438M ▼
Q3-2024 $0 $2.082M $-2.044M 0% $-0.14 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.642M ▲ $7.633M ▲ $83.926K ▼ $7.549M ▲
Q2-2025 $730.475K ▼ $868.318K ▼ $298.459K ▲ $569.859K ▼
Q1-2025 $1.206M ▼ $1.4M ▼ $106.173K ▼ $1.294M ▼
Q4-2024 $2.833M ▼ $2.923M ▼ $723.349K ▲ $2.2M ▼
Q3-2024 $4.145M $4.267M $692.833K $3.574M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-22.694M ▼ $-1.097M ▼ $0 $3.008M ▲ $1.911M ▲ $-1.097M ▼
Q2-2025 $-1.538M ▲ $-799.651K ▲ $0 $323.841K ▲ $-475.81K ▲ $-799.651K ▲
Q1-2025 $-1.784M ▲ $-1.63M ▲ $0 $3.381K ▼ $-1.627M ▼ $-1.63M ▲
Q4-2024 $-2.4M ▼ $-1.805M ▲ $0 $493.401K ▼ $-1.312M ▼ $-1.805M ▲
Q3-2024 $-2.044M $-1.842M $0 $3.163M $1.321M $-1.842M

Five-Year Company Overview

Income Statement

Income Statement MIRA is still a pure research-stage company with no product sales yet, so its income statement is very simple: research and corporate costs, but no revenue. Losses are currently modest in size but consistent year after year, which is exactly what you would expect from an early clinical‑stage biotech that is funding trials and development without any commercial products on the market. The key driver to watch over time is not today’s loss level, but how expenses grow as clinical programs advance and whether that spending translates into clear clinical milestones.

Balance Sheet

Balance Sheet The reported balance sheet data here are effectively blank, which likely means this dataset is incomplete rather than that the company has no assets or cash. Conceptually, for a company like MIRA, the real balance‑sheet story is: cash raised from investors, little or no traditional debt, and most of the value sitting in intangible assets such as drug candidates and patents rather than in factories or equipment. The strength of MIRA’s balance sheet in practice will depend on its cash runway (how long it can fund trials at current spending levels) and its ability to access capital markets when more funds are needed.

Cash Flow

Cash Flow MIRA is using cash rather than generating it, as is typical at this stage. Operating cash outflows reflect spending on research, early clinical work, and corporate overhead, while investment in physical assets appears limited. Free cash flow is negative but still relatively contained, consistent with an organization that is just ramping up its clinical activities. The main risk on the cash‑flow side is funding: as trials progress and become larger and more complex, cash burn can rise meaningfully, so the company’s need for future capital raises is an important consideration.

Competitive Edge

Competitive Edge MIRA’s competitive position is built around a focused pipeline in neurological and neuropsychiatric conditions, with an emphasis on safer, convenient, oral medicines. Its two lead candidates, Ketamir‑2 and MIRA‑55, are designed to deliver benefits similar to ketamine and medical cannabis without the same level of psychotropic or intoxicating effects, and importantly have been determined by U.S. regulators not to be controlled substances. That combination—oral dosing, potential safety and tolerability advantages, and fewer regulatory restrictions—could be quite differentiating if clinical data ultimately support the preclinical promise. At the same time, MIRA is operating in highly competitive spaces (pain, depression, anxiety, cognition, obesity, addiction) where many larger and better‑funded players are also active, so robust data and clear clinical differentiation will be critical to standing out.

Innovation and R&D

Innovation and R&D Innovation is the core of MIRA’s story. Ketamir‑2 aims to be an improved, orally available ketamine‑like therapy with a potentially better side‑effect profile and a longer‑lasting active metabolite, initially targeting chemotherapy‑induced neuropathic pain and rapid‑acting antidepressant use. MIRA‑55 is a synthetic, single‑molecule marijuana analog designed to tap into the body’s endocannabinoid system for anxiety and cognitive issues, but without the high associated with THC. The company has layered on additional innovation with SKNY‑1 for obesity and nicotine addiction, broadening its reach into very large markets. Across these programs, MIRA holds key patents and exclusive rights in several regions, and is just beginning formal human trials—meaning scientific upside exists, but clinical and regulatory risk is still very high.

Summary

Overall, MIRA is an early‑stage, research‑driven biopharmaceutical company with no current revenue, ongoing operating losses, and negative cash flow, which is normal for its stage of development but also underscores its dependence on external financing. Its investment case rests almost entirely on the success of its pipeline: novel oral therapies for pain, depression, anxiety, cognitive decline, obesity, and nicotine addiction, all designed with a strong emphasis on safety, convenience, and non‑controlled‑substance status. The company appears to have a thoughtful scientific strategy and intellectual‑property protection, but faces the usual binary risks of drug development: clinical trial outcomes, regulatory decisions, competitive pressure, and the need to secure enough capital to fund its plans through to later stages. Progress of Phase 1 and Phase 2 trials, regulatory interactions, and any early signals of clinical benefit or safety issues will likely be the main determinants of how the story evolves from here.

NEWS

October 24, 2025 · 7:30 AM UTC

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Read more

October 16, 2025 · 7:30 AM UTC

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

Read more

September 30, 2025 · 7:30 AM UTC

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction

Read more

September 22, 2025 · 8:00 AM UTC

MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog

Read more

September 16, 2025 · 7:30 AM UTC

MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals

Read more